The DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, GLP-1 RAs are indicated for the treatment of type 2 diabetes (all) and obesity (liraglutide and semaglutide only) and have beneficial effects on patient-important outcomes such as weight loss, cardiovascular and kidney events, hepatic steatosis, and mortality.5,7–9,11,30”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, modern treatment guidelines for type 2 diabetes 154 and essential hypertension 155 (also nutrition related chronic diseases), do recommend a stepped care approach to pharmacotherapy.”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [154]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As a result, GLP-1 RAs are contraindicated for patients with a personal or family history of MTC or those with multiple endocrine neoplasia syndrome type 2.8,17,22”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“However, a 5% weight reduction is insufficient to improve many aspects of health, and greater weight losses confer greater benefits, 23,82,83 with some data suggesting that there may be a threshold effect for reduction in some important comorbidities such as CVD and diabetes remission.[84][85][86]”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 1,039
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Self-citation
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Sorted by citations
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Rosenstock, J., Bain, S. C., Gowda, A., Jódar, E., Liang, B., Lingvay, I., Nishida, T., Trevisan, R., & Mosenzon, O. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303208 · Cited by 170
Optimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial
Wang, G., Liu, X., Ying, Z., Yang, G., Chen, Z., Liu, Z., Zhang, M., Yan, H., Lu, Y., Gao, Y., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02552-9 · Cited by 156
Lam, T.-P., Tran, N.-V. N., Pham, L.-H. D., Lai, N. V.-T., Dang, B.-T. N., Truong, N.-L. N., Nguyen-Vo, S.-K., Hoang, T.-L., Mai, T. T., & Tran, T. (2024) · Natural Products and Bioprospecting · doi:10.1007/s13659-023-00424-w · Cited by 152
Mathieu, C., Ásbjörnsdóttir, B., BAJAJ, H. S., Lane, W. S., Matos, A. L. D. S. A., Murthy, S., Stachlewska, K., & Rosenstock, J. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00520-2 · Cited by 149
Lingvay, I., Asong, M., Desouza, C. V., Gourdy, P., Kar, S., Vianna, A. G. D., Vilsbøll, T., VINTHER, S. M., & Mu, Y. (2023) · JAMA · doi:10.1001/jama.2023.11313 · Cited by 144
Philis‐Tsimikas, A., Asong, M., Franek, E., Jia, T., Rosenstock, J., Stachlewska, K., Watada, H., & Kellerer, M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00093-1 · Cited by 146
Whitley, H. P., Trujillo, J. M., & Neumiller, J. J. (2023) · Clinical Diabetes · doi:10.2337/cd23-0023 · Cited by 132
van Zuylen, M. L., Siegelaar, S. E., Plummer, M. P., Deane, A. M., Hermanides, J., & Hulst, A. H. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.01.001 · Cited by 132
Gourdy, P., Darmon, P., Diévart, F., Halimi, J., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 141
Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Self-citationPierce, J. B., Vaduganathan, M., Fonarow, G. C., Ikeaba, U., Chiswell, K., Butler, J., DeVore, A. D., Heidenreich, P. A., Huang, J., Kittleson, M. M., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1266 · Cited by 120
Russell-Jones, D., Babazono, T., Cailleteau, R., Engberg, S., Irace, C., Kjaersgaard, M. I. S., Mathieu, C., Rosenstock, J., Woo, V., & Klonoff, D. C. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02179-7 · Cited by 115
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Schoretsanitis, G., Weiler, S., Barbui, C., Raschi, E., & Gastaldon, C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23385 · Cited by 107
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Lisco, G., Disoteo, O., Tullio, A. D., Geronimo, V. D., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R. C., Guastamacchia, E., Pergola, G. D., et al. (2023) · Nutrients · doi:10.3390/nu16010063 · Cited by 111
Artificial intelligence for diabetes care: current and future prospects
Sheng, B., Pushpanathan, K., Guan, Z., Lim, Q. H., Lim, Z. W., Yew, S. M. E., Goh, J. H. L., Bee, Y. M., Sabanayagam, C., Sevdalis, N., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00154-2 · Cited by 106
Pain-free oral delivery of biologic drugs using intestinal peristalsis–actuated microneedle robots
Gao, X., Li, J., Li, J., Zhang, M., & Xu, J. L. (2024) · Science Advances · doi:10.1126/sciadv.adj7067 · Cited by 98
Navaneethan, S. D., Bansal, N., Cavanaugh, K. L., Chang, A. R., Crowley, S. T., Delgado, C., Estrella, M. M., Ghossein, C., Ikizler, T. A., Koncicki, H. M., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.003 · Cited by 116
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
Jang, H., Kim, Y., Lee, D. H., Joo, S. K., Koo, B. K., Lim, S. K., Lee, W., & Kim, W. K. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8029 · Cited by 100
Ferreira, R. O. M., Trevisan, T., Pasqualotto, E., Chavez, M. P., Marques, B. F., Lamounier, R. N., & van de Sande-Lee, S. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0390 · Cited by 92
Lopez, A., & Pajimna, J. A. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-52603-5 · Cited by 91
Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
Kittipibul, V., Cox, Z. L., Chesdachai, S., Fiuzat, M., Lindenfeld, J. M., & Mentz, R. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.040 · Cited by 93
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 83
Advances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 90
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 81
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart
Santulli, G., Varzideh, F., Forzano, I., Wilson, S. M., Salemme, L., Donato, A. D., Lombardi, A., Rainone, A., Nunziata, L., Jankauskas, S. S., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.20598 · Cited by 80
L-Arginine in diabetes: clinical and preclinical evidence
Forzano, I., Avvisato, R., Varzideh, F., Jankauskas, S. S., Cioppa, A., Mone, P., Salemme, L., Kansakar, U., Tesorio, T., Trimarco, V., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01827-2 · Cited by 86
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 89
Cho, S. W., Kim, J. H., Choi, H. S., Ahn, H. Y., Kim, M. K., & Rhee, E. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.102 · Cited by 71
Froldi, G. (2024) · Pharmaceuticals · doi:10.3390/ph17040478 · Cited by 75
Patents and regulatory exclusivities on GLP-1 receptor agonists
Alhiary, R., Kesselheim, A. S., Gabriele, S., Beall, R. F., Tu, S. S., & Feldman, W. B. (2023) · JAMA · doi:10.1001/jama.2023.13872 · Cited by 67
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Mark, P. B., Sarafidis, P. A., Ekart, R., Ferro, C. J., Balafa, O. C., Fernández‐Fernández, B., Herrington, W. G., Rossignol, P., Vecchio, L. D., Valdivielso, J. M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad112 · Cited by 76
Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D., & Reboldi, G. (2024) · Biomolecules · doi:10.3390/biom14010137 · Cited by 74
GLP-1RA Use and Thyroid Cancer Risk
Brito, J. P., Herrin, J. S., SWARNA, K. S., Ospina, N. S., Montori, V. M., Toro-Tobón, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.4852 · Cited by 70
Youn, Y. J., Kim, S. Y., Jeong, H., Ah, Y., & Yu, Y. M. (2024) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2024.101131 · Cited by 66
Zikou, E., Dovrolis, N., Dimosthenopoulos, C., Gazouli, M., & Makrilakis, K. (2023) · Nutrients · doi:10.3390/nu15214663 · Cited by 68
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 69
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
Wysham, C., BAJAJ, H. S., Prato, S. D., Franco, D. R., Kiyosue, A., Dahl, D. B., Zhou, C., Carr, M. C., Case, M. G., & GONCALVES, L. F. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403953 · Cited by 61
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 65
Rivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara-Breitinger, K. M., Gulati, M., & Bakris, G. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15529 · Cited by 59
Caruso, I., Gioia, L. D., Molfetta, S. D., Cignarelli, A., Palmer, S. C., Natale, P., Strippoli, G. F., Perrini, S., Natalicchio, A., Laviola, L., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102181 · Cited by 59
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzı́k, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 56
Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research
Li, J. Z., & Li, Y. R. (2023) · Cardiology · doi:10.1159/000531432 · Cited by 57
Tirzepatide: A Review in Type 2 Diabetes
France, N. L., & Syed, Y. Y. (2024) · Drugs · doi:10.1007/s40265-023-01992-4 · Cited by 51
Management of diabetic ketoacidosis
Barski, L., Golbets, E., Jotkowitz, A., & Schwarzfuchs, D. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.07.005 · Cited by 51
Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J., Wen, Y., Liu, H., Ye, H., Wang, J., & Wang, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01118-6 · Cited by 48
Solis‐Herrera, C., Kane, M. P., & Triplitt, C. L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0118 · Cited by 57
Giustina, A., Uygur, M. M., Frara, S., Barkan, A. L., Biermasz, N. R., Chanson, P., Freda, P. U., Gadelha, M. R., Haberbosch, L., Kaiser, U. B., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01397-w · Cited by 45
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
See, K. C. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1178 · Cited by 43
Danne, T. P. A., Joubert, M., Hartvig, N. V., Kaas, A., Knudsen, N. N., & Mader, J. K. (2024) · Diabetes Care · doi:10.2337/dc23-2176 · Cited by 42
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
Lauffenburger, J. C., Yom‐Tov, E., Keller, P. A., McDonnell, M. E., Crum, K. L., Bhatkhande, G., Sears, E. S., Hanken, K. E., Bessette, L. G., Fontanet, C. P., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01028-5 · Cited by 43
Kongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182037 · Cited by 43
Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
Hu, J.-C., Shao, S., Tsai, D. H., Chuang, A. T.-M., Liu, K., & Lai, E. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0946 · Cited by 42
Fu, E. L., Wexler, D. J., CROMER, S. J., Bykov, K., Paik, J. M., & Patorno, E. (2024) · BMJ · doi:10.1136/bmj-2023-078483 · Cited by 40
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 43
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Yokose, C., McCormick, N., Abhishek, A., Dalbeth, N., Pascart, T., Lioté, F., Gaffo, A., FitzGerald, J. D., Terkeltaub, R. A., Sise, M. E., et al. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01092-x · Cited by 43
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
Ray, A., Paik, J. M., Wexler, D. J., Sreedhara, S. K., Bykov, K., Feldman, W. B., & Patorno, E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.7811 · Cited by 36
Reznik, Y., Carvalho, M., Fendri, S., Prevost, G., Chaillous, L., Riveline, J. P., Hanaire, H., Dubois, S., Houéto, P., Pasche, H., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15351 · Cited by 34
Kelepouris, E., Peter, W. L. S., Neumiller, J. J., & Wright, E. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01416-2 · Cited by 37
Key indices of glycaemic variability for application in diabetes clinical practice
Monnier, L., Bonnet, F., Colette, C., Renard, É., & Owens, D. R. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101488 · Cited by 35
Rabbani, N., & Thornalley, P. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1268308 · Cited by 36
Tawakey, S. H., Mansour, M., Soltan, A., & Salim, A. I. (2024) · Lab on a Chip · doi:10.1039/d4lc00365a · Cited by 33
Frias, J. P., De Block, C., Brown, K., Wang, H., Thomas, M. K., Zeytinoglu, M., & Maldonado, J. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae038 · Cited by 31
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Çaklılı, Ö. T., Cesur, M., Mikhailidis, D. P., & Rizzo, M. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392684 · Cited by 35
Amin, N. B., Frederich, R. C., Tsamandouras, N., Haggag, A. Z., Schuster, T., Żmuda, W., Palmer, A., Vasas, S., Buckley, G., Smith, T. R., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16005 · Cited by 35
Bechlioulis, A., Markozannes, G., Chionidi, I., Liberopoulos, E. N., Naka, K. Κ., Ntzani, E., Liatis, S., Rizzo, M., & Rizos, E. C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108436 · Cited by 31
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Forzano, I., Wilson, S. M., Lombardi, A., Jankauskas, S. S., Kansakar, U., Mone, P., Varzideh, F., & Santulli, G. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263354 · Cited by 33
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations
Galiero, R., Caturano, A., Vetrano, E., Monda, M., Marfella, R., Sardu, C., Salvatore, T., Rinaldi, L., & Sasso, F. C. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s390752 · Cited by 36
McCoy, R. G., Herrin, J., Swarna, K. S., Deng, Y., Kent, D. M., Ross, J. S., Umpierrez, G. E., Galindo, R. J., Crown, W. H., Borah, B. J., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00453-9 · Cited by 30
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Trevisan, R., Conti, M., & Ciardullo, S. (2024) · Diabetologia · doi:10.1007/s00125-024-06158-9 · Cited by 34
Bergenstal, R. M., Philis‐Tsimikas, A., Wysham, C., Carr, M. C., Bue‐Valleskey, J. M., Botros, F. T., Blevins, T., & Rosenstock, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15604 · Cited by 29
The role of bone in energy metabolism: A focus on osteocalcin
Smith, C., Lin, X., Parker, L., Yeap, B. B., Hayes, A., & Levinger, I. (2024) · Bone · doi:10.1016/j.bone.2024.117238 · Cited by 32
Ekpor, E., Osei, E., & Akyirem, S. (2023) · International Health · doi:10.1093/inthealth/ihad080 · Cited by 28
Albert, S. G., & Wood, E. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108777 · Cited by 30
Bakry, H. M., Mansour, N. O., Elkhodary, T. R., & Soliman, M. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1181312 · Cited by 28
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 33
Self-citationRaiten, J. M., Morlok, A. P., D'Ambrosia, S., Ruggero, M. A., & Flood, J. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.10.011 · Cited by 33
Initial Combination Therapy in Type 2 Diabetes
Kim, J. Y., & Kim, N. H. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1816 · Cited by 35
Alnuaimi, S., Reljic, T., Abdulla, F. S., Memon, H., Al-Ali, S., Smith, T., Serdarević, F., Velija-Ašimi, Z., Kumar, A., & Semiz, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-59390-z · Cited by 30
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 29
Candido, R., Gaiotti, S., Giudici, F., Toffoli, B., Luca, F. D., Velardi, V., Petrucco, A., Gottardi, C., Manca, E., Buda, I., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186052 · Cited by 29
Guidelines on the Management of Type 2 Diabetes
Fisher, M. (2022) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1761205 · Cited by 28
Pai, Y., Chen, I., Lin, J., Chen, X., Chen, H., Chang, M., Huang, J., & Lin, C. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15918 · Cited by 26
Yang, T., Zhou, Y. F., & Cui, Y. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2288897 · Cited by 26
Huynh, D. J., Renelus, B. D., & Jamorabo, D. S. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-03085-8 · Cited by 29
Zhang, W., Wang, Y., Zhang, X., Zhang, Y., Yu, W., Tang, H., & Yuan, W. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03190-8 · Cited by 26
Htoo, P. T., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Everett, B. M., Glynn, R. J., Schmedt, N., Koeneman, L., Déruaz‐Luyet, A., Paik, J. M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02150-0 · Cited by 27
Design and In Silico Evaluation of an Exercise Decision Support System Using Digital Twin Models
Young, G. M., Dodier, R. H., Youssef, J. E., Castle, J. R., Wilson, L. M., Riddell, M. C., & Jacobs, P. G. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223217 · Cited by 26
Metadata
- Authors
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Aroda, Vanita R.
- Bannuru, Raveendhara R.
- Brown, Florence M.
- Bruemmer, Dennis
- Collins, Billy S.
- Hilliard, Marisa E.
- Isaacs, Diana
- Johnson, Eric L.
- Kahan, Scott
- Khunti, Kamlesh
- Lyons, Sarah K.
- Perry, Mary Lou
- Prahalad, Priya
- Pratley, Richard E.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-12-12
- Volume
- 46
- Issue
- Supplement_1
- Pages
- S140-S157
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC9810476
- OpenAlex
- W4311264067
- Semantic Scholar
- f75bf88f7fa4c4c0cf940dad739ba96bb6d15d64
- Cited by
- 851
- References
- 114
- Citations by year
- 2026: 64 · 2025: 149 · 2024: 360 · 2023: 277 · 2022: 1
- FWCI
- 28.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, diabetes mellitus, antidiabetic drugs, clinical guidelines, treatment goals, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
